Drug firms eager for a US Food and Drug Administration proposed rule on novel OTC switches could help accelerate its development and publication by submitting switch proposals, says former Commissioner Scott Gottlieb.
“I think the best thing a sophisticated sponsor can do is challenge the system with a well-thought-out application. That then...







